RANI - NASDAQ
Rani Therapeutics Holdings, Inc.
$0.88
+2.9%Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
At a Glance
Live Snapshotrani
Net Common Stock Issuance
Last Annual Value
61.08M
3-Year CAGR
478%
5-Year CAGR
-3%
10-Year CAGR
%
Rani Therapeutics Holdings, Inc. Competitors Analysis of Net Common Stock Issuance
| Company | Net Common Stock Issuance | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Rani Therapeutics Holdings, Inc. NASDAQ:RANI | 61.08M | 436.7% | -3.7% | N/A | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 77.43M | 1031.8% | 4.3% | 16.6% | |
 Elicio Therapeutics, Inc. NASDAQ:ELTX | 26.83M | 57.6% | 205.2% | N/A | |
 Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP | 224.18M | 255.9% | 1.1% | 27.0% | |
 Annovis Bio, Inc. NYSE:ANVS | 34.60M | 27.0% | -5.8% | N/A | |
 AN2 Therapeutics, Inc. NASDAQ:ANTX | 113.00K | -89.0% | N/A | N/A | |
 Verrica Pharmaceuticals Inc. NASDAQ:VRCA | 50.07M | 18.2% | 12.2% | N/A | |
 X4 Pharmaceuticals, Inc. NASDAQ:XFOR | 238.53M | 58.4% | 26.3% | N/A | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 104.75M | 17.5% | 7.1% | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 2.58M | N/A | -40.4% | 0.9% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 74.01M | 69.8% | 22.3% | 52.2% |
Rani Therapeutics Holdings, Inc. Fair Value Envelope
Related Guides
Continue your RANI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.